ZENITH
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
- Stage
- inclusie
- Medicine
- Zilebesiran
- Population
- ASCVD
- Phase
- III
- First Patient In
- 15 April 2026
- Last Patient In
- 16 March 2028
- Last Patient Last Visit
- 17 February 2030
Inclusion period, 695 days remaining
National Lead
prof. dr. J.H. Cornel
Cardioloog
Study Director
dr. J.W.M. van Eck
Research arts
Office Contact
